Reviews in urology最新文献_第8页

Factors Associated With Postoperative Infection After Percutaneous Nephrolithotomy. 经皮肾镜取石术后感染的相关因素。

Reviews in urology Pub Date : 2018-01-01 DOI: 10.3909/riu0778

Win Shun Lai, Dean Assimos

{"title":"Factors Associated With Postoperative Infection After Percutaneous Nephrolithotomy.","authors":"Win Shun Lai, Dean Assimos","doi":"10.3909/riu0778","DOIUrl":"https://doi.org/10.3909/riu0778","url":null,"abstract":"Numerous studies have investigated risk factors for the development of postoperative infection in percutaneous nephrolithotomy (PCNL) patients. Herein, we describe our meta-analysis of the risk factors for the prediction of post-PCNL infectious complications. We searched electronic databases using a combination of the terms percutaneous nephrolithotomy, risk factors, infection, and sepsis. The primary outcome was post-PCNL infection as defined by fever >38°C or sepsis as defined by the Sepsis Consensus Definition Committee. Risk factors for infection in each study were identified and included for analysis if present in at least two studies. We used quantitative effect sizes in odds ratio to assess each endpoint. After application of criteria, 24 studies were found, of which 12 were prospective and 12 were retrospective. Of the prospective studies, preoperative urine culture, renal pelvis culture, stone culture, number of access points, hydronephrosis, perioperative blood transfusion, and struvite stone composition were found to be significantly associated with postoperative infection. Of the 12 retrospective studies, preoperative urine culture, stone cultures, number of access points, blood transfusion, stone size, and staghorn formation were associated with infection. Preoperative urine culture, stone culture, number of access points, and need for blood transfusion were consistently found to be significant factors. This indicates that the presence of bacteria in the urine/stone preoperatively as well as the amount of trauma the kidney sustains during the procedure are major predictors of postoperative infection.","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"7-11"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3909/riu0778","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36255994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Botulinum Toxin Use in Neurourology. 肉毒杆菌毒素在神经病学中的应用。

Reviews in urology Pub Date : 2018-01-01 DOI: 10.3903/riu0792

Benoit Peyronnet, Xavier Gamé, Gregory Vurture, Victor W Nitti, Benjamin M Brucker

{"title":"Botulinum Toxin Use in Neurourology.","authors":"Benoit Peyronnet, Xavier Gamé, Gregory Vurture, Victor W Nitti, Benjamin M Brucker","doi":"10.3903/riu0792","DOIUrl":"https://doi.org/10.3903/riu0792","url":null,"abstract":"The use of botulinum toxin A (BTX-A) has revolutionized the treatment of neurogenic lower urinary tract dysfunction (NLUTD) over the past three decades. Initially, it was used as a sphincteric injection for detrusor sphincter dyssynergia but now is used mostly as intradetrusor injection to treat neurogenic detrusor overactivity (NDO). Its use is supported by high-level-of-evidence studies and it has become the gold-standard treatment for patients with NDO refractory to anticholinergics. Several novelties have emerged in the use of BTX-A in neurourology over the past few years. Although onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA) remains the only BTX-A for which use is supported by large, multicenter, randomized, controlled trials (RCT), and is therefore the only one to be licensed in the United States and Europe, a second BTX-A, abobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Basking Ridge, NJ), is also supported by high-level-of-evidence studies. Other innovations in the use of BTX-A in neurourology during the past few years include the BTX switch (from abobotulinumtoxinA to onabotulinumtoxinA or the opposite) as a rescue option for primary or secondary failures of intradetrusor BTX-A injection and refinements in intradetrusor injection techniques (number of injection sites, injection into the trigone). There is also a growing interest in long-term failure of BTX-A for NDO and their management, and a possible new indication for urethral sphincter injections.","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 2","pages":"84-93"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3903/riu0792","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36599628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

LUGPA Celebrates Its 10th Anniversary at Its 2018 Annual Meeting. LUGPA在2018年年会庆祝成立十周年。

Reviews in urology Pub Date : 2018-01-01 DOI: 10.3909/riu0816

Neal D Shore

引用次数: 1

Infertility in Patients With Klinefelter Syndrome: Optimal Timing for Sperm and Testicular Tissue Cryopreservation. 克氏综合征患者的不孕症:精子和睾丸组织冷冻保存的最佳时机。

Reviews in urology Pub Date : 2018-01-01 DOI: 10.3909/riu0790

Dorota J Hawksworth, April A Szafran, Philip W Jordan, Adrian S Dobs, Amin S Herati

引用次数: 21

Nocturia: Evaluation and Current Management Strategies. 夜尿症:评估与当前管理策略。

Reviews in urology Pub Date : 2018-01-01 DOI: 10.3909/riu0797

Casey G Kowalik, Joshua A Cohn, Sophia Delpe, W Stuart Reynolds, Melissa R Kaufman, Doug F Milam, Alan J Wein, Roger R Dmochowski